Virtual Pharma R&D: Open For Business
Open, or virtual, R&D is a current reality but could pharmaceutical companies embrace it more completely and execute it differently to deliver more substantial benefits? Charles River Associates looks to other industries to identify six drivers for success.
You may also be interested in...
Johnson & Johnson believes its future success is directly dependent on its ability to access best-in-class science via more flexible, less risky partnerships. The health care giant's global head of pharmaceutical R&D, Paul Stoffels, explains in greater detail J&J's open innovation model.
LEGO's approach to crowd control.
Examples of external innovation resources.